Benitec Biopharma (NASDAQ:BNTC – Get Free Report) had its price objective increased by research analysts at Leerink Partners from $18.00 to $18.27 in a research report issued on Monday, Benzinga reports. The brokerage currently has an “outperform” rating on the biotechnology company’s stock. Leerink Partners‘s target price suggests a potential upside of 108.42% from the stock’s previous close.
Other equities analysts have also issued research reports about the company. Royal Bank Of Canada upgraded Benitec Biopharma to an “outperform” rating in a research note on Tuesday, September 15th. Wedbush boosted their price target on Benitec Biopharma from $17.00 to $20.00 and gave the company an “outperform” rating in a research note on Monday. HC Wainwright restated a “buy” rating on shares of Benitec Biopharma in a research note on Monday, November 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Benitec Biopharma in a report on Thursday, October 15th. Finally, Citigroup reiterated a “market outperform” rating on shares of Benitec Biopharma in a research report on Tuesday, October 6th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Benitec Biopharma has a consensus rating of “Moderate Buy” and an average target price of $21.85.
Get Our Latest Stock Report on Benitec Biopharma
Benitec Biopharma Stock Down 3.0%
Shares of NASDAQ:BNTC traded down $0.27 during midday trading on Monday, hitting $8.77. The stock had a trading volume of 23,618 shares, compared to its average volume of 148,232. The company has a market cap of $305.85 million, a P/E ratio of -8.63 and a beta of 0.26. Benitec Biopharma has a 12 month low of $7.89 and a 12 month high of $14.39. The business’s 50-day simple moving average is $9.67 and its 200-day simple moving average is $11.39.
Benitec Biopharma (NASDAQ:BNTC – Get Free Report) last announced its quarterly earnings results on Friday, November 13th. The biotechnology company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.02. As a group, equities analysts predict that Benitec Biopharma will post -1.35 earnings per share for the current year.
Institutional Investors Weigh In On Benitec Biopharma
A number of hedge funds have recently made changes to their positions in BNTC. GAMMA Investing LLC increased its holdings in Benitec Biopharma by 18.7% in the 2nd quarter. GAMMA Investing LLC now owns 7,961 shares of the biotechnology company’s stock worth $107,000 after acquiring an additional 1,256 shares during the last quarter. Bank of America Corp DE lifted its holdings in Benitec Biopharma by 43.3% during the first quarter. Bank of America Corp DE now owns 17,376 shares of the biotechnology company’s stock valued at $185,000 after purchasing an additional 5,251 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in Benitec Biopharma by 37.6% during the first quarter. Bank of New York Mellon Corp now owns 43,489 shares of the biotechnology company’s stock valued at $463,000 after purchasing an additional 11,877 shares during the last quarter. ADAR1 Capital Management LLC purchased a new stake in Benitec Biopharma during the first quarter valued at about $186,000. Finally, AWM Investment Company Inc. purchased a new stake in Benitec Biopharma during the second quarter valued at about $2,515,000. 52.19% of the stock is currently owned by institutional investors and hedge funds.
About Benitec Biopharma
Benitec Biopharma is a clinical-stage biotechnology company developing genetic medicines for serious diseases. Its approach uses DNA-directed RNA interference (ddRNAi), a technique designed to reduce the production of disease-causing proteins by directing cells to silence specific genes. The company’s lead investigational candidate, BB-301, is being developed for oculopharyngeal muscular dystrophy (OPMD), a rare inherited disorder that can cause progressive muscle weakness and difficulty swallowing.
Further Reading
- Five stocks we like better than Benitec Biopharma
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
- Embraer’s Record Backlog Looks Promising, But Can It Keep Its Margins Climbing?
- Could Big Buybacks Be the Next Catalyst for These 3 AI Stocks?
- 3 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?
Receive News & Ratings for Benitec Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Benitec Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
